Long-term effectiveness of denosumab on bone density in rheumatic diseases implies important treatment insights.
We read with great interest the article by Furukawa et al, titled "Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases."¹ The authors9 comprehensive evaluation of bone mineral density (BMD) changes over 7 years in patients with rheumatic diseases (RDs) provides critical insights into the long-term efficacy and safety of denosumab in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: